NCT02208973View on ClinicalTrials.gov

"Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-680 After Multiple Oral Doses"

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2014

Conditions

Asthma

Interventions

DRUG

PBF-680

5, 10, 20, 40 and 60 mg of PBF-680

DRUG

Placebo

placebo for the dose of 5, 10, 20 and 40 mg of PBF-680

Trial Locations (2)

08025

CIM-Sant Pau - IIB Sant Pau, HSCSP, Barcelona

08302

Palobiofarma S.L. (molecule owner), Mataró

Sponsors

Collaborators (1)

Palo Biofarma, S.L

All Listed Sponsors

collaborator

Palo Biofarma, S.L

INDUSTRY

lead

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER